BidaskClub upgraded shares of Reata Pharmaceuticals (NASDAQ:RETA) from a sell rating to a hold rating in a research report released on Saturday morning.
RETA has been the topic of a number of other research reports. ValuEngine lowered Reata Pharmaceuticals from a hold rating to a sell rating in a research note on Thursday, November 9th. Zacks Investment Research upgraded Reata Pharmaceuticals from a strong sell rating to a hold rating in a research note on Tuesday, October 24th. Robert W. Baird restated a buy rating and set a $47.00 price objective on shares of Reata Pharmaceuticals in a research note on Tuesday, October 24th. Cowen restated a buy rating on shares of Reata Pharmaceuticals in a research note on Thursday, December 14th. Finally, Jefferies Group restated a buy rating and set a $44.00 price objective on shares of Reata Pharmaceuticals in a research note on Friday, October 6th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company. Reata Pharmaceuticals currently has a consensus rating of Buy and an average target price of $54.71.
Reata Pharmaceuticals (NASDAQ:RETA) traded up $0.18 during trading on Friday, reaching $29.79. The company’s stock had a trading volume of 105,856 shares, compared to its average volume of 135,187. Reata Pharmaceuticals has a 12-month low of $19.48 and a 12-month high of $40.88. The company has a debt-to-equity ratio of -0.15, a quick ratio of 3.18 and a current ratio of 3.18. The company has a market cap of $777.91, a price-to-earnings ratio of -19.47 and a beta of -3.11.
In other Reata Pharmaceuticals news, Director Cpmg Inc purchased 200,000 shares of the firm’s stock in a transaction dated Thursday, December 14th. The shares were bought at an average price of $24.79 per share, for a total transaction of $4,958,000.00. Following the purchase, the director now owns 113 shares in the company, valued at approximately $2,801.27. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director James Edward Bass purchased 3,888 shares of the firm’s stock in a transaction dated Wednesday, November 15th. The stock was acquired at an average price of $24.02 per share, for a total transaction of $93,389.76. Following the purchase, the director now owns 52,089 shares in the company, valued at approximately $1,251,177.78. The disclosure for this purchase can be found here. In the last quarter, insiders bought 413,813 shares of company stock worth $10,453,354. Corporate insiders own 44.00% of the company’s stock.
Several institutional investors and hedge funds have recently modified their holdings of the company. Emerald Advisers Inc. PA increased its stake in shares of Reata Pharmaceuticals by 40.1% in the 3rd quarter. Emerald Advisers Inc. PA now owns 569,416 shares of the company’s stock valued at $17,709,000 after purchasing an additional 162,990 shares during the last quarter. Emerald Mutual Fund Advisers Trust boosted its holdings in shares of Reata Pharmaceuticals by 60.9% during the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 473,051 shares of the company’s stock valued at $14,712,000 after acquiring an additional 179,124 shares in the last quarter. FMR LLC boosted its holdings in shares of Reata Pharmaceuticals by 74.4% during the 2nd quarter. FMR LLC now owns 414,491 shares of the company’s stock valued at $13,114,000 after acquiring an additional 176,885 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Reata Pharmaceuticals by 109.6% during the 2nd quarter. Vanguard Group Inc. now owns 295,540 shares of the company’s stock valued at $9,350,000 after acquiring an additional 154,515 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its holdings in shares of Reata Pharmaceuticals by 78.1% during the 2nd quarter. JPMorgan Chase & Co. now owns 232,562 shares of the company’s stock valued at $7,359,000 after acquiring an additional 101,969 shares in the last quarter. Institutional investors own 29.58% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “BidaskClub Upgrades Reata Pharmaceuticals (RETA) to Hold” was first posted by Markets Daily and is the sole property of of Markets Daily. If you are accessing this story on another publication, it was stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.themarketsdaily.com/2018/01/21/bidaskclub-upgrades-reata-pharmaceuticals-reta-to-hold.html.
Reata Pharmaceuticals Company Profile
Reata Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases.
Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.